Prurisol is a plus, not a minus. Given the strong pre-clinicals and the small signal bump in the Phase 2A, there's a chance the higher dose 2B shows good signal, in which case we have an extremely viable and attractive commercial psoriasis drug. Don't let the pumping make you skeptical, every biotech has its pumping as well as bashing.
K just got pushed back a bit, but it's still exciting times for this company.
News 
Market Data 
Discover 
